Association Between Immune-Related Adverse Events During Anti–PD-1 Therapy and Tumor Mutational Burden

This database study compares surveillance data on immune-related adverse events (irAEs) in patients treated with immune checkpoint inhibitors to determine whether irAEs experienced during anti–PD-1 therapy correlate with tumor mutational burden across 18 cancer types.

Detalles Bibliográficos
Autores principales: Bomze, David, Hasan Ali, Omar, Bate, Andrew, Flatz, Lukas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Medical Association 2019
Materias:
Research Letter
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6707013/
https://www.ncbi.nlm.nih.gov/pubmed/31436791
http://dx.doi.org/10.1001/jamaoncol.2019.3221
Descripción
Sumario:This database study compares surveillance data on immune-related adverse events (irAEs) in patients treated with immune checkpoint inhibitors to determine whether irAEs experienced during anti–PD-1 therapy correlate with tumor mutational burden across 18 cancer types.

Ejemplares similares